Effect of Enamel Matrix Derivative or Hyaluronic Acid on Non-Surgical Treatment of Peri-Implantitis

Launched by GAZI UNIVERSITY · Sep 26, 2024

Keywords

ClinConnect Summary

This clinical trial is studying how effective two different treatments—enamel matrix derivative (EMD) and hyaluronic acid (HA)—are when added to standard non-surgical therapy for a condition called peri-implantitis, which is an infection that affects the tissues around dental implants. The goal is to see if using either EMD or HA along with the standard treatment leads to better patient outcomes after one year compared to the standard treatment alone.

To participate in the trial, you need to be at least 18 years old and in good health, with dental implants that have been in place for more than a year. However, if you have certain health issues, smoke heavily, or have specific dental problems, you may not be eligible. If you join the study, you can expect to receive either EMD or HA with your treatment, and you will have follow-up assessments at various points over the next year to monitor your progress and gather your feedback about the treatment. This information will help researchers understand which treatment option is more effective for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Systemically healthy and ≥18 years of age,
• • Implants with an SLA® or SLActive® surface (Straumann Dental Implant System, Institute Straumann AG) have been in function for more than 1 year,
• • Implant-supported prostheses accessible for self-performed plaque control and submarginal instrumentation,
• • Absence of implant mobility.
• Exclusion Criteria:
• • Full-mouth plaque score (FMPS) \> 20%
• • Full-mouth bleeding score (FMBS) \> 20%
• • Cigarette smoking \> 10 cig./day,
• • Diagnosed with active periodontal disease,
• • Having acute or chronic medical conditions or undergoing medications, such as intravenous amino-bisphosphonates, immunosuppressive drugs, and chemotherapy, that could interfere with the treatment outcome,
• • Receiving antibiotic treatment in the previous 3 months.